DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension.

Author(s): Kandavar R, Higashi Y, Chen W, Blackstock C, Vaughn C, Sukhanov S, Sander GE, Roffidal LE, Delafontaine P, Giles TD

Affiliation(s): Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA.

Publication date & source: 2011-05, J Am Soc Hypertens., 5(3):161-5. Epub 2011 Jan 19.

Publication type: Comparative Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

This study sought to determine if metoprolol succinate ER (MET), and nebivolol (NEB), a beta1-AR with increased bioavailability of nitric oxide (NO), would have differing effects on plasma asymmetric dimethylarginine concentration in hypertensives. It was hypothesized that NEB, a beta1-AR antagonist and beta3-AR agonist with NO-releasing properties, and MET, only a beta1-AR antagonist, would have different effects on plasma asymmetric dimethylarginine (ADMA) concentration. Forty-one hypertensive subjects randomly received either 50 mg of MET (n = 19) or 5 mg of NEB (n = 22) for 4 weeks followed by 100 mg MET and 10 mg NEB for 4 weeks. ADMA and insulin-like growth factor-1 (IGF-1) were measured by enzyme-linked immunosorbent assay kit; endothelial progenitor cells were estimated using fluorescein-labeled monoclonal antibody to KDR and CD133 receptors; arterial augmentation index was measured by radial tonometry. Baseline systolic/diastolic blood pressure was 155.1 +/- 18.7/85.3 +/- 12.5 mm Hg for MET subjects and 157.6 +/- 20.7/87.1 +/- 14.0 mm Hg for NEB subjects. Baseline ADMA was 0.32 +/- 0.123 mumol/L in the MET group and 0.4035 +/- 0.1378 in the NEB group. ADMA increased 44.78% and 72% in the MET group at weeks 4 and 8 (P < .05 for both), respectively, without increase in the NEB group. At week 8, augmentation index was increased in the MET group (P < .05). IGF-1 and endothelial progenitor cells were unchanged by treatment. Plasma ADMA and augmentation index are increased in a dose-dependent fashion by MET but not with NEB. Copyright (c) 2011 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017